Digestive Enzymes

The VerdictMODERATE CONVICTIONWorth-It: Situational ROI (58/100)

The prescription enzyme that works for chronic pancreatitis is not the OTC capsule you are buying for bloating.

If you do not have a doctor-diagnosed pancreatic condition and you are reaching for a £30-£50 multi-enzyme blend for bloating or "leaky gut," do not buy it. Track food and symptoms for two weeks, do a structured low-FODMAP elimination with a dietitian, and consider SIBO breath testing + coeliac screening. Workup the cause. Enzymes are not in that pathway. What this is: Digestive enzymes are two completely different products sold under one name. Prescription pancrelipase is a porcine pancreatic extract that replaces what the pancreas no longer makes in chronic pancreatitis and cystic fibrosis — FDA-approved, 40 years of evidence. Over-the-counter "broad-spectrum plant-based" blends combine plant proteases, lactase, and alpha-galactosidase in one capsule and are marketed for healthy-adult bloating and "general digestion" — a separate product category with no RCT evidence base for its claims.

In 30+ years of the OTC digestive-enzyme market, zero placebo-controlled trials have tested multi-enzyme blends against placebo for healthy-adult bloating, IBS, or "leaky gut." The absence of the trial design despite billions in category sales is the strongest evidence-of-absence signal you can read.
Most adults with lactose intolerance tolerate about one cup of milk (12-15 grams of lactose) at one sitting when spaced with other foods. Lactase tablets are a convenience layer for when you exceed the threshold, not a population-level first-line.
If you have confirmed exocrine pancreatic insufficiency, take prescription pancrelipase at 40,000-50,000 lipase units with the first bite of every meal, half-dose with snacks, with a PPI if response is inadequate. Forty percent of real-world prescriptions sit below the guideline dose — diarrhoea improves, weight does not.

That's the general answer. Your stack is different.

Check your whole stack

If you do not have a doctor-diagnosed pancreatic condition and you are reaching for a £30-£50 multi-enzyme blend for bloating, do not buy it.

Track food and symptoms for two weeks. Do a structured low-FODMAP elimination with a dietitian. Consider SIBO breath testing and coeliac screening. Workup the cause. Enzymes are not in that pathway.

The Verdict

The prescription enzyme that works for chronic pancreatitis is not the OTC capsule you are buying for bloating.

What this is: Digestive enzymes are two completely different products sold under one name. Prescription pancrelipase is a porcine pancreatic extract that replaces what the pancreas no longer makes in chronic pancreatitis and cystic fibrosis. Over-the-counter “broad-spectrum plant-based” blends combine plant proteases, lactase, and alpha-galactosidase in one capsule and are marketed for healthy-adult bloating and general digestion.

The pancreas is a digestive juice factory that runs all day, producing about one to two litres of fluid containing enzymes that break down fats, proteins, and starches in the upper gut. When the factory is destroyed by disease, you can buy the chemicals it used to make and take them with every meal. When the factory works perfectly and you take those same chemicals for bloating, you are not fixing anything. The bloating is downstream of fermentation in a different stretch of the gut, and the enzymes you are taking do not work there.

In 30+ years of the OTC digestive-enzyme market, zero placebo-controlled trials have tested multi-enzyme blends for healthy-adult bloating, IBS, or “leaky gut.” The absence of the trial design despite billions in category sales is the strongest evidence-of-absence signal you can read.
Most adults with lactose intolerance tolerate about one cup of milk (12-15 grams of lactose) at one sitting when spaced with other foods. Lactase tablets are a convenience layer for when you exceed the threshold, not the population-level first line.
If you have confirmed exocrine pancreatic insufficiency, take prescription pancrelipase at 40,000 to 50,000 lipase units with the first bite of every meal, half-dose with snacks, with a PPI if response is inadequate. Forty percent of real-world prescriptions sit below the guideline dose — diarrhoea improves, weight does not.

Best for

Adults and children with confirmed exocrine pancreatic insufficiency (chronic pancreatitis, cystic fibrosis, post-pancreatic-resection, advanced pancreatic cancer). Adults with confirmed lactose intolerance who exceed the 12-15 g tolerance threshold. Adults with recurrent legume-induced flatulence.

Skip if

You are a healthy asymptomatic adult reaching for a multi-enzyme blend for “general gut health” or bloating. You are taking enzymes for “protein absorption.” You have coeliac disease and are considering DPP-IV enzymes as a gluten-free diet substitute.

Want the full evidence? Keep scrolling.

The Protocol

What to take, how much, when. No mechanism, no debate.

Dosing

Population	Dose	Timing	Form	Source
Adult EPI (chronic pancreatitis, CF, post-resection)	40,000-50,000 lipase units / meal, half-dose with snacks	At meal start; redose mid-meal for large meals	Enteric-coated pancrelipase (Creon, Zenpep, Pancreaze, Ultresa)	de la Iglesia-García 2017 PMID 27941156; AGA 2023 PMID 37737818; Cattaneo 2025 PMID 40169459
Adult EPI with inadequate response	Add a PPI (omeprazole, lansoprazole) to improve duodenal pH	Once daily	Standard PPI dose	de la Iglesia-García 2017 dose-response subanalysis
Paediatric cystic fibrosis	500-2,500 LU lipase / kg / meal, capped at 10,000 LU / kg / day	At meal start	Enteric-coated pancrelipase	CF Foundation; PMID 21632288
Advanced pancreatic cancer + nutritional decline	40,000-75,000 LU / meal under oncologist supervision	At meal start	Enteric-coated pancrelipase	Roberts 2021 PMID 33522321
Adult lactose intolerance — population first line	≤12-15 g lactose / sitting (~1 cup milk) spaced with other foods	With meals containing fat and protein	Whole-food approach (yoghurt, hard cheese, lactose-spaced milk)	Wilt 2010 AHRQ SR PMID 20404262
Adult lactose intolerance — convenience layer	3,000-9,000 FCC lactase units	With first sip of dairy	Lactase tablet / drops or pre-hydrolysed milk	Wilt 2010
Adult with legume-induced flatulence	1,200 GalU alpha-galactosidase	At first bite of legume meal	Beano and generics	Di Stefano 2007 PMID 17151807
Healthy adult — “general digestion / bloating / IBS / leaky gut”	NOT EVIDENCE-SUPPORTED	N/A	N/A	NO RCT in 30+ years
Coeliac disease — DPP-IV as GFD substitute	NOT EVIDENCE-SUPPORTED	N/A	Strict gluten-free diet remains the only evidence-based management	Coeliac UK, BSG, NIH
Gym population — “protein absorption”	NOT EVIDENCE-SUPPORTED	N/A	Healthy pancreas produces massive protease excess	Debunked by physiology

Forms Comparison

Enteric-coated pancrelipase (Creon, Zenpep, Pancreaze, Ultresa)

pH 1-2 survival → release at pH ≥5.5

Best for: Confirmed exocrine pancreatic insufficiency only. The only product with FDA approval + guideline dosing.

Lactase tablets / drops

Co-meal in vivo activity, wasted without lactose

Best for: Adults with confirmed lactose intolerance exceeding tolerance threshold. ~£5-£15 / 60 tablets.

Pre-hydrolysed lactose-reduced milk

≥70% lactose hydrolysed at retail

Best for: Adults who prefer food format over tablet. ~1.5-2× standard milk.

Alpha-galactosidase (Beano)

1200 GalU acute breath-H₂ reduction

Best for: Recurrent legume-induced flatulence. Benign, acute-only. ~£5-£10 / 30 tablets.

Bromelain / Papain solo

Partially inactivated at gastric pH 1.5-2

Best for: Inflammation / DOMS / sinusitis (separate literature). NOT digestion.

Multi-enzyme “broad-spectrum plant-based” blend

DATA UNAVAILABLE — no RCT for marketed indication

Best for: No evidence-supported clinical-outcome indication. The premium-pricing layer of a product category with no clinical-outcome RCT. ~£20-£50 / 90 capsules.

DPP-IV “gluten digestion” enzymes

DATA UNAVAILABLE for restaurant-meal gluten loads

Best for: NO substitute for strict gluten-free diet. Coeliac societies do not endorse.

Betaine HCl “stomach acid” supplements

Not a digestive enzyme — gastric acidifier

Best for: NO evidence-supported use case in healthy adults. PPI deprescribing is a clinical decision.

Absorption Tips

PERT must be taken at meal start. Empty-stomach PERT is wasted dose. Redose mid-meal for large meals.
PERT + PPI improves duodenal pH for lipase activity in patients with inadequate response.
Lactase tablets must hit the lactose bolus — wasted without dairy. Drops added to milk an hour ahead also work.
Pre-hydrolysed dairy (Lactaid, Zymil) works at retail without a consumer enzyme decision at consumption.
For legume flatulence, food-first colonic adaptation over 2-4 weeks works too. Alpha-galactosidase is the acute convenience layer.

Safety & Interactions

Drug Interactions

PERT + acarbose / miglitol (T2D)

Mutual antagonism — PERT amylase digests starches that acarbose is meant to delay. Coordinate with diabetes team if PERT introduced.

PERT + iron supplements / folic acid

Minor reduction in iron absorption; minor folic acid impairment. Separate iron by 1 h; monitor folate in long-term users.

High-dose bromelain + warfarin / DOACs / antiplatelets

Increased bleeding via fibrinolytic activity. Avoid high-dose bromelain peri-operatively (7-14 d pre-surgery hold) and in patients on anticoagulants.

Papain + warfarin

INR elevation in case reports. Avoid or close INR monitoring.

Contraindicated Populations

Active acute pancreatitis flare: Hold PERT during the attack; reintroduce when oral feeds resume.
Pork allergy, religious-dietary objection (Jewish, Muslim, halal, kosher, vegetarian, vegan): Pancrelipase is porcine-derived; few non-porcine prescription alternatives exist.
Classical galactosaemia: Lactase tablets contraindicated — hydrolysis produces galactose.
Active GI bleeding or peri-operative window (7-14 d pre-surgery): Avoid high-dose bromelain or papain.
Cystic fibrosis paediatric population: Cap pancrelipase at 10,000 LU lipase / kg / day to avoid fibrosing colonopathy.
Coeliac disease using DPP-IV enzymes as a GFD substitute: Active negative endorsement from coeliac societies — strict gluten-free diet remains the only evidence-based management.

Side Effects

PERT — nausea, GI cramping, perianal irritation in young children during dose-titration (mild, common). Fibrosing colonopathy is rare and dose-related (>10,000 LU/kg/d in paediatric CF). Porcine hypersensitivity is rare. Lactase and alpha-galactosidase tablets have no significant RCT-pool side effects. High-dose bromelain carries bleeding and latex-fruit syndrome cross-reactivity. Multi-enzyme blend safety database: DATA UNAVAILABLE — no RCT-grade safety pool for general healthy-adult use.

Upper Limits

PERT (CF paediatric): 10,000 lipase units / kg / day (fibrosing colonopathy ceiling). PERT (adults): No formal UL; titrate by symptom + CFA. Practical ceiling ~75,000-90,000 LU / meal. OTC enzymes (lactase, alpha-gal): No formal UL established.

Conviction: MODERATE

Overall — sharply endpoint-stratified. PERT for confirmed EPI is HIGH. PERT for advanced pancreatic cancer + nutritional decline is MODERATE-HIGH. Lactase in-meal, pre-hydrolysed dairy, and alpha-galactosidase for their narrow indications are MODERATE / MODERATE-HIGH / LOW-MODERATE. Multi-enzyme blends for healthy-adult bloating, IBS, and “leaky gut” are NONE-to-LOW. DPP-IV as a gluten-free diet substitute is NONE NEGATIVE = HARM.

What would change this

An independent (non-supplement-industry-funded), double-blind, placebo-controlled, parallel-group RCT of N ≥ 200 healthy adults with self-reported chronic bloating but no diagnosed pancreatic / coeliac / IBD pathology, randomised to a typical OTC multi-enzyme blend at manufacturer’s recommended dose × 8 weeks, with a primary endpoint of IBS-SSS ≥30-point reduction or PRO-CTCAE bloating reduction vs placebo, would move the multi-enzyme blend verdict from NONE → LOW-MODERATE if it succeeded. The absence of this trial design in 30+ years of category sales is itself the strongest evidence-of-absence signal.

Worth Your Money?

Estimated weekly cost

Prescription PERT for confirmed EPI: £6-£50/week (covered or partially covered on most insurance / NHS). Lactase tablets: £1-£4/week. Alpha-galactosidase: £1-£3/week. Multi-enzyme “broad-spectrum” blend: £5-£12/week.

Worth it if

You have a confirmed pancreatic, lactose, or legume-flatulence indication and you are using the right product at the right dose. PERT for EPI is medical therapy, not optional.

Lower priority if

You are a healthy asymptomatic adult buying a multi-enzyme blend for “bloating” or “leaky gut.” Better first dollars: a low-FODMAP elimination consultation with a dietitian (£60-£150 once), a SIBO breath test if indicated, a coeliac screen, and time tracking food and symptoms. None of that costs more than a few months of the blend you were going to buy.

Conditional Value

Want to stop wasting money on supplements that don’t work? The Verdict reviews one every week — free.

Subscribe to The Verdict

Claims vs Evidence — See What the Research Found

What People Claim

Marketing layer 1 — prescription pancrelipase. Class-efficacy claims are honest: improves fat absorption, weight maintenance, and quality of life in exocrine pancreatic insufficiency. This is the only digestive-enzyme product with FDA approval and guideline-codified dosing.

Marketing layer 2 — targeted OTC enzymes (lactase, alpha-galactosidase / Beano). Claims map to narrow indications: helps you digest dairy, reduces gas after legumes. These are largely accurate within their labelled use, though they overstate the population that actually needs them.

Marketing layer 3 — multi-enzyme “broad-spectrum plant-based” blends. Claims go feral. Typical products combine amylase, protease, lipase, lactase, alpha-galactosidase, cellulase, bromelain, and papain in one capsule and market: bloating relief, IBS support, leaky gut healing, post-meal heaviness, low stomach acid, improved protein absorption for muscle building. None of these claims has an RCT-grade evidence base.

Marketing layer 4 — niche enzyme claims. DPP-IV “gluten digestion” enzymes are marketed for incidental gluten exposure in coeliac and non-coeliac gluten sensitivity. Betaine HCl is marketed for “low stomach acid.” Bromelain solo is marketed as a natural digestive aid alongside its inflammation / DOMS / sinusitis literature. The first claim is actively counterproductive — coeliac societies explicitly do not endorse DPP-IV as a gluten-free diet substitute.

What the Evidence Actually Shows

Claim	Strength	Effect size	Key study	Verdict
PERT for confirmed EPI (chronic pancreatitis, CF, post-resection, pancreatic cancer)	STRONG	CFA 83.2% vs 67.4% placebo, p=0.0001	de la Iglesia-García 2017 SR/MA N=511	Works — first-line medical therapy
PERT for advanced pancreatic cancer + nutritional decline	MODERATE-STRONG	Direction-positive survival + body weight + QoL	Roberts 2021 PMID 33522321 MA N=194	Works — under-prescribed in real-world
Lactase tablets in-meal for adult lactose intolerance	MODERATE	Symptom reduction when used with dairy bolus	Wilt 2010 AHRQ SR PMID 20404262	Works as labelled — but not population-level first line
Lactose-reduced / pre-hydrolysed dairy	MODERATE-STRONG	Pre-digested ex vivo ≥70% lactose hydrolysed	Wilt 2010	Works without consumer enzyme decision
Tolerance-threshold approach (≤12-15 g lactose / sitting)	STRONG	Tolerated by most adults with confirmed malabsorption	Wilt 2010 AHRQ SR	The population-level first line
Alpha-galactosidase for legume-induced flatulence	EMERGING	1200 GalU significantly reduced breath H₂ + flatulence (N=8 acute crossover)	Di Stefano 2007 PMID 17151807	Likely works acutely, no replication
RP-G28 GOS (prebiotic, NOT enzyme) for lactose intolerance	EMERGING	50% abdominal pain reduction, 6× more likely tolerance post-treatment	Savaiano 2013 RCT N=85 [industry-funded]	Promising — colonic adaptation, not an enzyme
Lactase drops for infant colic	WEAK	Pooled MD -17.66 min/d crying, p=NS, I²=68%	Salvatore 2024 MA of 5 RCTs N=391	Inconclusive — pooled NULL
Multi-enzyme blends for healthy-adult bloating / IBS / leaky gut / general digestion	DEBUNKED-by-absence	No RCT in 66-paper sweep	—	Unsupported — no evidence base in 30+ years
Bromelain / papain for “digestive aid” in healthy adults	DEBUNKED-by-absence	No RCT for digestive-aid endpoint	—	Unsupported for the digestive claim
Betaine HCl for “low stomach acid” in healthy adults	DEBUNKED-by-absence	No RCT in sweep	—	Unsupported
DPP-IV enzymes as gluten-free diet substitute in coeliac	NONE — HARM	Coeliac societies explicitly do not endorse	Coeliac UK, BSG, NIH	Do not use as GFD substitute
“Enzymes with protein for muscle absorption” (gym population)	DEBUNKED-by-physiology	Healthy pancreas produces 1-2 L pancreatic juice / day with massive protease excess	—	Decoration, not digestion
Premium plant-based multi-enzyme > prescription PERT at matched indication	DEBUNKED-by-absence	No head-to-head RCT; different regulatory categories	—	Class category confusion
Hard CV outcomes, mortality, cancer, longevity	NONE	No trial design exists	—	Not in the evidence base

The Full Picture — Mechanism, Debate & Nuance

How It Works

Pancrelipase (prescription PERT) replaces destroyed exocrine pancreatic function. The pancreas normally secretes 1-2 litres of digestive juice per day containing lipase, protease, and amylase that hydrolyse fats, proteins, and starches in the duodenum. When the pancreas is destroyed by chronic pancreatitis, cystic fibrosis, pancreatic resection, or advanced pancreatic cancer, this secretion fails and the patient develops malabsorption — the defining clinical feature is steatorrhoea (greasy, floating, foul-smelling stools) because lipase is rate-limiting. Pancrelipase is porcine pancreatic enzyme extract, enterically coated as pH-sensitive minispheres or microtablets that survive gastric acid at pH 1-2 and release at pH ≥5.5 in the proximal jejunum, replacing what the patient cannot secrete. Coefficient of fat absorption (CFA) recovery from below 60% to 80-90% is the canonical biomarker; weight stabilisation and reduced steatorrhoea are the clinical endpoints.

Lactase, alpha-galactosidase, bromelain, papain (OTC enzymes) are substrate-specific hydrolases that act in the gut lumen on a single class of dietary substrate. Lactase hydrolyses the lactose disaccharide into absorbable monomers in the upper small bowel. Alpha-galactosidase hydrolyses the alpha-1,6 galactosidic bonds in raffinose, stachyose, and verbascose oligosaccharides in legumes, reducing the fermentable load that colonic bacteria convert to gas. Bromelain (pineapple stem) and papain (papaya latex) are plant proteases studied mainly for their systemic effects after absorption — inflammation, DOMS, sinusitis. Their role in luminal digestion is plausible but unstudied at clinical-outcome endpoints in healthy adults, and gastric acid partially inactivates them before they reach the duodenum unless enterically coated.

Multi-enzyme blends combine the substrate-specific enzymes from layer 2 with bromelain + papain in one capsule and market a generic “supports digestion / reduces bloating / heals leaky gut” claim. Mechanistically this is just the sum of each enzyme’s lumenal action — there is no synergistic mechanism that makes the blend more than the sum of its parts, and no clinical-outcome RCT has tested the blend against placebo for the consumer indications. The pharmacology is plausible for the substrate-specific enzymes acting on their substrates; the marketing reach beyond that pharmacology is what fails the evidence test.

The Debate

Symptom relief vs nutritional repletion — the PERT dose-response split

Cattaneo 2025 real-world SR (PMID 40169459, N=3,818)

40% of EPI patients receive sub-guideline PERT doses. Diarrhoea improves on those lower doses. Nutritional status does not.

de la Iglesia-García 2017 SR/MA (PMID 27941156, N=511)

Higher-dose, enteric-coated, in-meal-administered PERT outperformed low-dose / non-coated on coefficient of fat absorption.

The European 40,000-50,000 LU / meal guideline is calibrated to nutritional repletion, not symptom relief. Same dose-response pattern as CoQ10 SAMS at 100 vs 300 mg — biomarker moves at low dose, clinical outcome requires higher.

Lactase for infant colic — the heterogeneity-outlier pattern

Bauer 2018 single-centre RCT (PMID 30504935, N=104)

Lactase drops significantly reduced crying duration (86.5% vs 59.6% improvement, p<0.05) at 2 weeks.

Salvatore 2024 pooled MA (PMID 38426798, 5 RCTs N=391)

Pooled effect on crying duration NULL (MD -17.66 min/d, p=NS, I²=68%). Three of five RCTs at high risk of bias.

Single-centre positive RCT is the heterogeneity-driving outlier; broader pooled evidence does not support population-level efficacy. Same pattern as 1980s GLA for atopic dermatitis — single-trial positive vs pooled NULL.

30+ years of OTC multi-enzyme blend marketing — and zero RCTs

OTC supplement market

Billions in annual sales of multi-enzyme “broad-spectrum plant-based” blends marketed for healthy-adult bloating, IBS, “leaky gut,” general digestion.

66-paper sweep across PubMed and OpenAlex

ZERO placebo-controlled RCTs testing OTC multi-enzyme blends for any of those healthy-adult endpoints.

The absence of the trial design despite the size of the market is the strongest evidence-of-absence signal you can read. The product category exists without a primary evidence base.

Tolerance-threshold vs marketing — adult lactose intolerance

Wilt 2010 AHRQ SR (PMID 20404262)

~12-15 g lactose (≈1 cup milk) tolerated by most adults with confirmed lactose malabsorption when spaced with food.

Retail lactase market

Tablets sold to anyone reporting any dairy-associated symptom, with no stratification on tolerance threshold.

Population-level tolerance threshold vs individual-symptom marketing. The lactase indication is real but narrower than the market presents — food-spacing is the population-level first line.

Honest Limitations

Indication-population mismatch is the dominant consumer failure mode

Prescription PERT exists because the pancreas is destroyed. The OTC multi-enzyme blend market sells to asymptomatic healthy adults whose bloating is FODMAP fermentation, SIBO, functional dyspepsia, or microbiome dysbiosis — enzymes are not the active ingredient in any of these. The consumer reaching for a multi-enzyme blend is solving the wrong problem.

PERT real-world under-dosing

Forty percent of EPI patients receive sub-guideline doses (Cattaneo 2025 PMID 40169459). Symptom relief masks nutritional failure. If you are on PERT and still losing weight, ask your gastroenterologist whether your dose is at guideline.

Product-quality variation in OTC multi-enzyme blends is uncharacterised

Prescription PERT brands undergo FDA dose-uniformity assays; even regulated products vary in release kinetics (D’Haese 2025 PMID 40569561). OTC multi-enzyme blends are not subject to potency-uniformity regulation. Label claims cannot be cross-validated against an FDA standard.

Premium pricing buys a marketing label

There is no head-to-head RCT between a premium “broad-spectrum plant-based” multi-enzyme blend and prescription pancrelipase, nor between premium and standard OTC blends at matched dosing. The premium is the marketing layer, not the clinical layer — the prebiotic premium-synbiotic problem and the krill-oil premium-omega-3 problem, replayed.

The Nuance

Population stratification. The same word “enzyme” covers two regulatory categories: prescription medical therapy for a destroyed organ, and dietary supplement for general wellness. The first is high-conviction, evidence-rich, prescriber-supervised. The second is unregulated, low-evidence, marketing-driven. The consumer market does not signal this boundary, which is how an asymptomatic adult ends up paying £40 a month for a product whose first-cousin product saves the lives of cystic fibrosis patients.

Cost-effectiveness. For confirmed EPI, prescription PERT at £25-£200 a month (insurance / NHS-covered) is medical therapy — there is no food alternative. For lactose intolerance, pre-hydrolysed milk at retail is the food alternative, and the food-spacing approach (≤12-15 g lactose per sitting with meals) is the population-level first line. For legume flatulence, gradual fibre exposure adapts the colonic microbiota over 2-4 weeks. For healthy-adult chronic bloating, the budget moves to a low-FODMAP consultation with a dietitian (£60-£150 once), a SIBO breath test if indicated, and a coeliac screen.

Food-first alternatives. Pressure-cooking beans and discarding the soak water reduces oligosaccharide load. Yoghurt and hard cheese are naturally low in lactose. Mediterranean and high-fibre diets supply the prebiotic substrate that the multi-enzyme blend is supposedly “digesting better.” The healthy pancreas already produces a litre or two of digestive juice every day with massive enzyme excess for the protein, fat, and starch load of a normal diet — including the gym population’s high-protein intake.

Sources

de la Iglesia-García D, et al. (2017). Efficacy of pancreatic enzyme replacement therapy in chronic pancreatitis: systematic review and meta-analysis. Gut. 66(8):1354-1360. PMID 27941156. SR/MA of 14 RCTs N=511; CFA 83.2% vs 67.4% placebo, p=0.0001.
Chu P, Mioc J, O’Donovan P, Henry O. (2025). Clinical Efficacy and Safety of Treatments for Exocrine Pancreatic Insufficiency: A Systematic Literature Review. Digestion. PMID 39299226. AbbVie-affiliated SLR; class efficacy; Creon vs Zenpep CNA-72h NS between products.
Cattaneo D, et al. (2025). Pancreatic Enzyme Replacement Therapy in Pancreatic Exocrine Insufficiency — Real-World’s Dosing and Effectiveness: A Systematic Review. Nutrients. PMID 40169459. SR of 25 observational studies N=3,818; 40% sub-guideline dosing.
Phillips ME, et al. (2023). AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency. Gastroenterology. PMID 37737818. Codifies fecal elastase <200 µg/g diagnosis + 40,000-50,000 LU/meal dose.
Wilt TJ, et al. (2010). Lactose intolerance and health. AHRQ Evidence Report. PMID 20404262. SR of 36 RCTs; 12-15 g lactose tolerated by most adults with malabsorption.
Di Stefano M, et al. (2007). The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms. Dig Dis Sci. PMID 17151807. Crossover RCT N=8; 1200 GalU significantly reduced breath H₂ + flatulence.
Salvatore S, et al. (2024). Effect of lactase supplementation on infant colic: Systematic review of randomized controlled trials. J Pediatr Gastroenterol Nutr. PMID 38426798. SR/MA of 5 RCTs N=391; pooled NULL primary endpoint.
Roberts KJ, et al. (2021). Impact of pancreatic enzyme replacement therapy on short- and long-term outcomes in advanced pancreatic cancer: meta-analysis of randomized controlled trials. Expert Rev Gastroenterol Hepatol. PMID 33522321. MA 4 RCTs N=194; direction-positive survival + body weight + QoL.
Savaiano DA, et al. (2013). Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial. Nutr J. PMID 24330605. RCT N=85, GOS colonic-adaptation strategy; industry-funded.
Bauer Y, et al. (2018). Clinical Efficacy Of Lactase Enzyme Supplement In Infant Colic: A Randomised Controlled Trial. J Pak Med Assoc. PMID 30504935. Single-centre RCT N=104.
Ng C, Major G, Smyth AR. (2021). Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis. Cochrane Database Syst Rev. PMID 34339047.
D’Haese JG, et al. (2025). In-Vitro Comparison of Physical Characteristics, Enzyme Content, and Release Kinetics of Pancreatic Enzyme Preparations Available in Europe and Canada. PMID 40569561.

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score

58/100 Situational ROI Trust grade C

Conditional, and only with a real diagnosis. Prescription enzymes for a damaged pancreas work and are first-line, and single-target OTC enzymes help specific food intolerances, but the broad-spectrum blend most people buy for bloating has no evidence behind it.

Time

Low

Money

Medium

Effort

Low

Risk

Medium

Why this score

C-grade trust because the category is sharply stratified: prescription PERT for confirmed exocrine pancreatic insufficiency is STRONG (de la Iglesia-Garcia 2017, 14 RCTs, N=511: fat absorption 83.2% vs 67.4% placebo, p=0.0001), but the multi-enzyme blend marketed for healthy-adult bloating has zero RCTs in a 66-paper sweep across 30+ years.
Expected benefit depends entirely on diagnosis: high if you genuinely have EPI, confirmed lactose intolerance, or recurrent legume gas; effectively nil for the typical 'I feel bloated' buyer.
Time and effort cost are low (take a capsule with a meal), which is the main reason this is Situational rather than Low: the failure is targeting, not friction.
Money cost is Medium and often wasted: multi-enzyme blends run $20 to $50 a month with no evidence base, while the things that work for the common cases are cheap (lactase $5 to $15, alpha-galactosidase $5 to $10) or prescription.
Risk is Medium: mostly opportunity cost from delaying a proper workup, plus real harms in specific cases (high-dose bromelain raises bleeding risk with blood thinners, and DPP-IV 'gluten' enzymes used as a gluten-free-diet substitute in coeliac are actively counterproductive).

Why it didn’t score higher

The dominant consumer use (a broad-spectrum blend for bloating, IBS, or 'leaky gut') has no placebo-controlled evidence at all, despite billions in category sales, which is itself a strong evidence-of-absence signal.
Even the legitimate lactose case is usually better handled by the food-spacing approach (most adults with malabsorption tolerate about 12 to 15 g of lactose, roughly one cup of milk, with food, per Wilt 2010) than by a tablet.
Reaching for enzymes can delay the workup that actually finds the cause (FODMAP fermentation, SIBO, functional dyspepsia, coeliac), which has a real time-cumulative cost.

Best for

Adults and children with confirmed exocrine pancreatic insufficiency (chronic pancreatitis, cystic fibrosis, post-pancreatic-resection, advanced pancreatic cancer): prescription PERT is first-line medical therapy
Adults with advanced pancreatic cancer and nutritional decline, where PERT is under-prescribed (Roberts 2021)
Adults with confirmed lactose intolerance who exceed the ~12 to 15 g tolerance threshold or want empty-stomach dairy: lactase tablets or pre-hydrolyzed milk as a convenience layer
Adults with recurrent legume gas who have already tried gradual fiber adaptation: alpha-galactosidase 1200 GalU at first bite (Di Stefano 2007, cheap and benign)

Lower ROI if

Reader is a healthy adult using a multi-enzyme blend for general bloating, IBS, or 'leaky gut' (no evidence base for any of these).
Reader has lactose intolerance but tolerates about 12 to 15 g of lactose with food spacing (needs the strategy, not the tablet).
Reader is a gym-goer taking enzymes 'for protein absorption' (the healthy pancreas already makes a large protease excess: decoration, not digestion).
Reader has coeliac disease and is using DPP-IV 'gluten' enzymes as a gluten-free-diet substitute (active negative endorsement from coeliac societies).
Reader pays a premium for a 'broad-spectrum plant-based' blend expecting it to match prescription PERT (different products, different regulatory categories, no head-to-head trial).

Minimum effective dose

Diagnosis-specific. EPI: prescription enteric-coated pancrelipase at 40,000 to 50,000 lipase units with the first bite of each meal, half-dose with snacks, add a PPI if response is inadequate. Confirmed lactose intolerance: try the 12-to-15 g tolerance-threshold and food-spacing approach first, then 3,000 to 9,000 FCC lactase units with dairy as needed. Legume gas: 1200 GalU alpha-galactosidase at first bite. For general bloating in a healthy adult, there is no evidence-supported dose.

Track this

If on PERT: body weight and steatorrhea (greasy, floating stools); if still losing weight, you are likely under-dosed (40% of real prescriptions are below guideline, Cattaneo 2025)
If lactose-intolerant: symptoms against a known lactose amount, to find your personal threshold before defaulting to tablets
For general bloating: a 2-week food-and-symptom diary to guide a proper workup, not an enzyme trial
Whether the enzyme is being used to avoid a needed FODMAP elimination, SIBO test, or coeliac screen

The prescription enzyme that works for chronic pancreatitis is not the OTC capsule you are buying for bloating.

Best for

Skip if

The Protocol

Dosing

Forms Comparison

Absorption Tips

Safety & Interactions

Drug Interactions

PERT + acarbose / miglitol (T2D)

PERT + iron supplements / folic acid

High-dose bromelain + warfarin / DOACs / antiplatelets

Papain + warfarin

Contraindicated Populations

Side Effects

Upper Limits

Worth Your Money?

What People Claim

What the Evidence Actually Shows

How It Works

The Debate

Symptom relief vs nutritional repletion — the PERT dose-response split

Lactase for infant colic — the heterogeneity-outlier pattern

30+ years of OTC multi-enzyme blend marketing — and zero RCTs

Tolerance-threshold vs marketing — adult lactose intolerance

Honest Limitations

Indication-population mismatch is the dominant consumer failure mode

PERT real-world under-dosing

Product-quality variation in OTC multi-enzyme blends is uncharacterised

Premium pricing buys a marketing label

The Nuance

Sources

Action ROI

Get the complete dosing protocol

Related free research

There are 424 more inside